A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

Phase

Condition

Atopic Dermatitis

Dermatitis, Atopic

Allergy

Treatment

Lutikizumab

Clinical Study ID

NCT06524635

M24-922

Ages 18-75
All Genders

Study Summary

Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD.

Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS and AD. This study will consist of 2 sub-studies: Sub-Study 1 moderate to severe hidradenitis suppurativa and Sub-Study 2 moderate to severe atopic dermatitis. Approximate 60 participants will be enrolled in the study at approximately 2 sites in the US.

In Sub-Study 1 HS participants will receive subcutaneous (SC) injections of lutikizumab for up to week 15 with a 70-day follow-up period. In Sub-Study 2 AD, participants will receive subcutaneous (SC) injections of lutikizumab for up to week 14 with a 70-day follow-up period. The study duration for Sub-Studies 1 and 2 is expected to last up to 30 weeks.

Participants in Sub-Study 1 (HS) who complete Week 16 and showed a therapeutic benefit to lutikizumab, as confirmed by the investigator, will have the option to enter an open-label long-term extension (LTE) to continue to receive lutikizumab for up to an additional 140 weeks, followed by a 70-day follow-up period.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and biomarker collections.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Sub-Study 1 hidradenitis suppurativa (HS):
Participants with a diagnosis of moderate-to-severe HS for at least 6 months priorto Baseline as determined by the investigator
Participants naïve to biologic treatment for HS or must have a prior inadequateresponse or loss of response to anti-TNF therapy for HS (>= 12 weeks of therapy).
Sub-Study 2 atopic dermatitis (AD):
Participants with a diagnosis of moderate-to-severe AD with onset of symptoms atleast 1 year prior to Baseline.
Participants naïve to biologic treatment for AD or must have a prior inadequateresponse or loss of response to dupilumab for AD (defined as >= 8 weeks of therapywith dupilumab).

Exclusion

Exclusion Criteria:

History of any malignancy within the last 5 years except for successfully treatednonmelanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.
History of active skin disease (other than HS for Sub-Study 1 or AD for Sub-Study 2)that could interfere with the assessment of HS (for Sub-Study 1) or AD (forSub-Study 2), including skin infections (e.g., bacterial, fungal, or viral)requiring systemic treatment within 4 weeks of the Baseline.

Study Design

Lutikizumab

August 14, 2024

February 28, 2027

Connect with a study center

Physioseq, LLC /ID# 267266
Sacramento, California 95825
United States
Active - Recruiting
University of Michigan Health System - Ann Arbor /ID# 267275
Ann Arbor, Michigan 48109
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.